The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its legacy within the broader industry now presents questions about long-term gains. Alternative versions are diminishing patent protection , leading to worries that supporting companies significantly dependent to Viagra's once-dominant influence could